This proposal is for a five year renewal (years 6-10) of a Program Project to pursue gamma-secretase modulating compounds as Alzheimer's disease (AD) therapeutics at the University of California, San Diego, consortium with Mayo Clinic Jacksonville and Washington University, St Louis. In the first five years of support, we have shown that nonsteroidal anti-inflammatory drugs (NSAIDs) have a novel secondary action that modulates gamma-secretase processing in a cyclooxygenase (COX) independent manner. The activity of a subset of NSAIDs preferentially lowers the amyloidogenic A?42 peptide both in vitro and in vivo, leading us to propose that this activity may be one explanation for the apparent risk reduction of AD in chronic NSAID users. As we have identified many compounds in addition to NSAIDs that shift gamma secretase cleavage, we now generically refer to these compounds as gamma-secretase modulators (GSMs). Our research efforts have contributed to the introduction of the first GSM, R-flurbiprofen ("Flurizan" renamed Tarenflurbil") into the clinic for testing in AD treatment, and led to the preclinical development of additional GSMs. The two major goals of this PPG are to further understand the mechanism of action of GSMs, and to test their activity in humans as well as determine their ability to lower disease-associated biomarkers in AD individuals. Project 1 will examine the site of action of GSMs with respect to effects on gamma- versus epsilon-cleavage and test the efficacy of combination treatments in rodents. Project 2, which has now incorporated the former Chemistry Core, will extend studies relating to the binding site of multiple GSMs, examine the relative contribution of GSMs with respect to reducing A?42 production vs. inhibiting A? aggregation, and conduct animal studies to better define how GSMs acutely alter A? levels in the brain, CSF, and plasma of mouse AD models. Projects 1 and 2 will coordinately examine the biological properties of shorter A? peptides which are elevated by these GSMs. Project 3 will determine if R-flurbiprofen lowers A?42 in human CSF by measuring newly synthesized A? through in-dwelling catheter and will test whether a GSM (ibuprofen) will reduce disease associated CSF biomarkers and brain volumetric changes by neuroimaging in AD subjects in a one year placebo controlled double-blind treatment study. Successful completion of these studies will provide greater insight into 1) how the GSMs shift gamma cleavage, 2) how GSMs attenuate AD-like phenotypes in rodent models, and 3) how GSMs and GSM based NSAIDs may work in humans. By providing additional preclinical and clinical information on GAMs, such studies should contribute significantly to the further development of GSMs as Alzheimer's therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG020206-09
Application #
8306822
Study Section
Special Emphasis Panel (ZAG1-ZIJ-3 (O3))
Program Officer
Refolo, Lorenzo
Project Start
2002-04-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
9
Fiscal Year
2012
Total Cost
$976,709
Indirect Cost
$229,491
Name
University of California San Diego
Department
Neurosciences
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Nhan, Hoang S; Chiang, Karen; Koo, Edward H (2015) The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol 129:19-Jan
Ran, Yong; Cruz, Pedro E; Ladd, Thomas B et al. (2014) ýý-Secretase processing and effects of ýý-secretase inhibitors and modulators on long A* peptides in cells. J Biol Chem 289:3276-87
Chiang, Karen; Koo, Edward H (2014) Emerging therapeutics for Alzheimer's disease. Annu Rev Pharmacol Toxicol 54:381-405
Jung, Joo In; Ran, Yong; Cruz, Pedro E et al. (2014) Complex relationships between substrate sequence and sensitivity to alterations in ?-secretase processivity induced by ?-secretase modulators. Biochemistry 53:1947-57
Golde, Todd E; Koo, Edward H; Felsenstein, Kevin M et al. (2013) ?-Secretase inhibitors and modulators. Biochim Biophys Acta 1828:2898-907
Jung, Joo In; Ladd, Thomas B; Kukar, Thomas et al. (2013) Steroids as ýý-secretase modulators. FASEB J 27:3775-85
Chu, Jin; Giannopoulos, Phillip F; Ceballos-Diaz, Carolina et al. (2012) Adeno-associated virus-mediated brain delivery of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol Neurodegener 7:1
Kukar, Thomas L; Ladd, Thomas B; Robertson, Paul et al. (2011) Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid ? peptide length: support for a sequential model of ?-secretase intramembrane proteolysis and regulation by the amyloid ? precursor protein (APP) juxtamembrane region. J Biol Chem 286:39804-12
Sagi, Sarah A; Lessard, Christian B; Winden, Kellen D et al. (2011) Substrate sequence influences ?-secretase modulator activity, role of the transmembrane domain of the amyloid precursor protein. J Biol Chem 286:39794-803
Golde, Todd E; Schneider, Lon S; Koo, Edward H (2011) Anti-a? therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69:203-13

Showing the most recent 10 out of 22 publications